Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if the drug NULOJIX® (belatacept) will minimize the
amount of other anti-rejection medications necessary and thereby reduce the long-term side
effects caused by the other medications. The researchers also want to learn more about the
safety of this treatment and long term health of transplanted pancreases and kidneys.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Bristol-Myers Squibb Clinical Trials in Organ Transplantation Rho Federal Systems Division, Inc.